Posted by magann14 on 18th of Apr 2011 at 01:17 pm
Neoprobe continues to
provide a good amount of upside potential, as it is very close to
filing a new drug application with the FDA and has recently moved
onto a major stock exchange.
Over the next 12 months, Neoprobe Corporation
has a chance to go from producing 10 million in annual revenue to
over $450 million in annual revenue.
Over the next 2-3 years, there is even greater
potential for Neoprobe Corp to produce over $2-3 billion in annual
revenue.
NEOP has remained stable as the underlying
market is being whipped around. On NEOP, there are open interests
of 30987 option calls (bullish) at various strike prices and there
are open interests of 1223 option puts (bearish) at various strike
prices. So the ratio there is like 30:1, which needless to
say is bullish on the underlying stock price. If that ratio
were flip flopped, that would be bearish on the stock.
We are within 30 days of top line data on the last Lymphoseek
trial, 45-60 days from New Drug Application filing for Lymphoseek,
90-180 days from approved trial design for RIGScan CR phase 3
trial, 6-9 months from Lymphoseek approval and 10-12 months from
RIGScan CR phase 3 trial. I do not see anything negative for
the next 12 months.
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
NEOP
Posted by mlorr on 18th of Apr 2011 at 12:56 pm
Looks great here at 4.25... i'm in at 4.21.
Told myself i wasnt going to trade today and celebrate AMRN... oh well that didnt work!
Neoprobe continues to provide a good
Posted by magann14 on 18th of Apr 2011 at 01:17 pm
Neoprobe continues to provide a good amount of upside potential, as it is very close to filing a new drug application with the FDA and has recently moved onto a major stock exchange. Over the next 12 months, Neoprobe Corporation has a chance to go from producing 10 million in annual revenue to over $450 million in annual revenue. Over the next 2-3 years, there is even greater potential for Neoprobe Corp to produce over $2-3 billion in annual revenue. NEOP has remained stable as the underlying market is being whipped around. On NEOP, there are open interests of 30987 option calls (bullish) at various strike prices and there are open interests of 1223 option puts (bearish) at various strike prices. So the ratio there is like 30:1, which needless to say is bullish on the underlying stock price. If that ratio were flip flopped, that would be bearish on the stock. We are within 30 days of top line data on the last Lymphoseek trial, 45-60 days from New Drug Application filing for Lymphoseek, 90-180 days from approved trial design for RIGScan CR phase 3 trial, 6-9 months from Lymphoseek approval and 10-12 months from RIGScan CR phase 3 trial. I do not see anything negative for the next 12 months.